Cytokine-Based immunotherapy, Volume 396, Part A delves into the intricate world of cytokines, vital signaling proteins that orchestrate the immune response and their pivotal role in modulating various immune functions. From their fundamental mechanisms to their therapeutic applications, this book offers a thorough examination of the latest trends and developments in leveraging cytokines for immunotherapy. The book includes chapters such as Cytokine-driven cancer immune evasion mechanisms, which explores how cytokines contribute to cancer cells' ability to evade the immune system. Cytokine-based immunotherapy in hematolymphoid malignancies is also explored, discussing the use of cytokines in treating blood cancers.
Targeting TNF-alpha examines the immunotherapeutic approach for alleviating neuropathic pain. The key role of immunomodulatory cytokines for the development of novel nk cell-based cancer therapies focuses on the importance of cytokines in developing new cancer treatments. Finally, complexities in the clinical development of TGF? inhibitors covers the challenges in creating inhibitors for TGF?.
Targeting TNF-alpha examines the immunotherapeutic approach for alleviating neuropathic pain. The key role of immunomodulatory cytokines for the development of novel nk cell-based cancer therapies focuses on the importance of cytokines in developing new cancer treatments. Finally, complexities in the clinical development of TGF? inhibitors covers the challenges in creating inhibitors for TGF?.
Table of Contents
1. Cytokine-driven cancer immune evasion mechanismsEnrique Javier Arenas Lahuerta
2. Cytokine-based immunotherapy in hematolymphoid malignancies
M�rio Sousa Pimenta Sr. and Nuno R. dos Santos
3. Targeting TNF-alpha: An immunotherapeutic approach for alleviating neuropathic pain
Mario Garc�a Dom�nguez
4. The key role of immunomodulatory cytokines for the development of novel nk cell-based cancer therapies
Maite Alvarez, Cristina Eguizabal, Anne Etxebarria, Diego Barriales and Andrea Saez de C�mara
5. Complexities in the clinical development of TGF? inhibitors
Javier Dotor
6. Dichotomy of IL-27 in tumor immunity
Fernando Aranda
